Topiramate Tablet, Film Coated
Product Images NDC 70518-4340

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-4340). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This text provides information about Topiramate tablets containing 50 mg, with a quantity of 100 per box. It includes storage instructions, dosage details, the manufacturer (Glenmark), and contact details for RemedyRepack Inc., in Indiana, PA. The NDC number and LOT number are also provided for reference. The text emphasizes protecting the medication from moisture and keeping it out of the reach of children.*

FDA Label Image

Mm2 (Topiramate 50mg 70518 4340 01)

This description provides details about a topiramate tablet, with a dosage of 50 mg. It includes information on how to store the medication, instructions to protect it from moisture, the usual dosage recommendations, and the manufacturer (Glenmark). The text also mentions the NDC number, quantity, and the company that repackaged the tablet (RemedyRepack Inc.).*

FDA Label Image

Figure1 (Figure1)

This text provides information on cumulative rates for time to first seizure associated with two different doses of Topiramate (50 mg/day and 400 mg/day) over a period of time (in days). The data is presented in a graphical format showing the cumulative rates on the y-axis and time in days on the x-axis. The total number of participants for each dosage is also provided (N=234 for 50 mg/day and N=238 for 400 mg/day).*

FDA Label Image

Figure2 (Figure2)

The text describes a study comparing the effectiveness of different doses of Topiramate and a placebo in reducing the average monthly migraine period rate. The study includes various dosage groups ranging from 50 mg/day to 200 mg/day, and the results are presented in terms of changes from baseline to double-blind evaluation. The statistical significance levels for the results are also provided.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.